Munich-based Ethris has secured €30M from the European Investment Bank to push its respiratory mRNA pipeline deeper into clinical testing.
The company designs therapies around two proprietary platforms: Stabilized Non-Immunogenic mRNA, known as SNIM RNA, and Stabilized NanoParticle lipid nanoparticles, or SNaP. Together they are meant to deliver stabilised mRNA directly to the airways through optimised formulation and nebulisation.
Its lead candidate, ETH47, encodes interferon lambda and is designed for local delivery to the respiratory tract by inhalation or nasal spray. The goal is mucosal immunity rather than the systemic response produced by injected vaccines.
Chief executive Carsten Rudolph said the funding advances clinical development across the respiratory portfolio. The unmet need is real: respiratory infections remain among the leading causes of hospitalisation, and injected delivery struggles to generate protection at the site of infection.
The EIB’s involvement signals continued European appetite for backing deeptech biotech through debt-like instruments rather than equity, a structure that lets founders avoid dilution while paying for expensive trials.
Ethris sits in a crowded field. Several groups are pursuing inhaled mRNA, and the winner will likely be decided by tolerability and repeat dosing rather than by delivery concept alone.
